Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Remdesivir

- PMLiVE

Cancer Research UK study finds different responses to COVID-19 among cancer patients

Some blood cancer patients took five times longer than average to recover from the virus

- PMLiVE

FDA will not alter dosing schedules for authorised COVID-19 vaccines

Time period between first and second vaccines has been extended in the UK

- PMLiVE

Inovio plans late-stage COVID-19 vaccine study in second quarter 2021

FDA had placed trial on a temporary hold in September 2020

- PMLiVE

Pfizer/BioNTech to offer COVID-19 vaccine to placebo recipients

Only those trial participants who are currently eligible under the EUA will be offered the vaccine

- PMLiVE

Sinopharm’s COVID-19 vaccine scores approval in China

Vaccine found to be 79% effective in top-line results

- PMLiVE

First person in the UK given AstraZeneca/Oxford University COVID-19 vaccine

The vaccine can be stored at standard refrigerator temperatures

- PMLiVE

Abivax’s COVID-19 study declared Research National Priority by French government

Drug treatment is being investigated in high-risk COVID-19 patients

- PMLiVE

CureVac set to begin phase 3 COVID-19 vaccine study in healthcare workers

First participant will be vaccinated on 22 December

- PMLiVE

J&J completes enrolment for late-stage COVID-19 vaccine trial

Company announces that around 45,000 participants have been enrolled

- PMLiVE

Valneva launches phase 1/2 COVID-19 vaccine trials in the UK

UK government has pre-ordered 60 million doses of candidate

- PMLiVE

Sanofi, GSK delay COVID-19 vaccine trial after underwhelming results in elderly participants

Phase 2b study has been delayed to February 2021

- PMLiVE

J&J trims the size of its phase 3 COVID-19 vaccine trial

Company cuts size of participant population from 60,000 to 40,000

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links